

## Newbury Pharmaceuticals Q3 - Sales Ramp-up

Redeye provides a research update following the Q3 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, COGS, and net sales. However, we reiterate our fair value range with a base case valuation of SEK8.5 as our outlook on the case remains positive.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Newbury Pharmaceuticals Q3 - Sales Ramp-up](#)